Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRP203 in Subacute Cutaneous Lupus Erythematosus
NCT01294774Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of mocravimod in subacute cutaneous lupus erythematosus (SCLE), sponsored by Novartis. Started Feb 2011; status: completed.
02
Drugs
mocravimod
03
Conditions
subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on NCT01294774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01294774.